The genetic epidemiology of breast cancer genes

被引:171
作者
Thompson, D [1 ]
Easton, D [1 ]
机构
[1] Univ Cambridge, Canc Res UK Genet Epidemiol Unit, Strangeways Res Lab, Cambridge CB1 8RN, England
关键词
breast cancer; BRCA1; BRCA2; ATM; CHEK2; TP53; PTEN;
D O I
10.1023/B:JOMG.0000048770.90334.3b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic susceptibility to breast cancer in women is conferred by a large number of genes, of which six have so far been identified. In the context of multiple-case families, BRCA1 and BRCA2 are the most important. Mutations in these genes confer high lifetime risks of breast cancer and ovarian cancer, and more moderate risks of prostate cancer and some other cancer types. Mutations in the CHEK2 and ATM genes, by contrast, cause much more modest (2-4 fold) risks of breast cancer. Genes so far identified explain approximately 20% of the familial aggregation of breast cancer. The remaining susceptibility genes have, so far, proved illusive, suggesting that they are numerous and confer moderate risks. A variety of techniques including genome-wide association studies, use of quantitative intermediate endpoints, and resequencing of genes may be required to identify them. The identification of such genes can provide a basis for targeted prevention of breast cancer.
引用
收藏
页码:221 / 236
页数:16
相关论文
共 138 条
[51]   A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability [J].
Healey, CS ;
Dunning, AM ;
Teare, MD ;
Chase, D ;
Parker, L ;
Burn, J ;
Chang-Claude, J ;
Mannermaa, A ;
Kataja, V ;
Huntsman, DG ;
Pharoah, PDP ;
Luben, RN ;
Easton, DF ;
Ponder, BAJ .
NATURE GENETICS, 2000, 26 (03) :362-364
[52]  
Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741
[53]   Biallelic inactivation of BRCA2 in Fanconi anemia [J].
Howlett, NG ;
Taniguchi, T ;
Olson, S ;
Cox, B ;
Waisfisz, Q ;
de Die-Smulders, C ;
Persky, N ;
Grompe, M ;
Joenje, H ;
Pals, G ;
Ikeda, H ;
Fox, EA ;
D'Andrea, AD .
SCIENCE, 2002, 297 (5581) :606-609
[54]   Genome-wide scanning for linkage in Finnish breast cancer families [J].
Huusko, P ;
Juo, SHH ;
Gillanders, E ;
Sarantaus, L ;
Kainu, T ;
Vahteristo, P ;
Allinen, M ;
Jones, M ;
Rapakko, K ;
Eerola, H ;
Markey, C ;
Vehmanen, P ;
Gildea, D ;
Freas-Lutz, D ;
Blomqvist, C ;
Leisti, J ;
Blanco, G ;
Puistola, U ;
Trent, J ;
Bailey-Wilson, J ;
Winqvist, R ;
Nevanlinna, H ;
Kallioniemi, OP .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (02) :98-104
[55]  
Jakubowska A, 2003, CANCER EPIDEM BIOMAR, V12, P457
[56]   Gene expression profiles, of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers [J].
Jazaeri, AA ;
Yee, CJ ;
Sotiriou, C ;
Brantley, KR ;
Boyd, J ;
Liu, ET .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (13) :990-1000
[57]  
Johannesdottir G, 1996, CANCER RES, V56, P3663
[58]   Tumour biological features of BRCA1-induced breast and ovarian cancer [J].
Johannsson, OT ;
Idvall, I ;
Anderson, C ;
Borg, A ;
Barkardottir, RB ;
Egilsson, V ;
Olsson, H .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) :362-371
[59]   CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers [J].
Kadouri, L ;
Easton, DF ;
Edwards, S ;
Hubert, A ;
Kote-Jarai, Z ;
Glaser, B ;
Durocher, F ;
Abeliovich, D ;
Peretz, T ;
Eeles, RA .
BRITISH JOURNAL OF CANCER, 2001, 85 (01) :36-40
[60]   Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers [J].
Kadouri, L ;
Kote-Jarai, Z ;
Easton, DF ;
Hubert, A ;
Hamoudi, R ;
Glaser, B ;
Abeliovich, D ;
Peretz, T ;
Eeles, RA .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) :399-403